Talquetamab Phase 3 Trial for Multiple Myeloma Reaches Primary Completion

The Phase 3 study (NCT06208150) investigating talquetamab in participants with relapsed or refractory multiple myeloma reached its primary completion on April 23, 2026. This trial compares talquetamab in combination with other agents against standard regimens for this patient population.

Background

Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow. Relapsed or refractory multiple myeloma refers to the disease that has returned or not responded to previous treatments, posing a significant challenge for patients and clinicians.

Trial design

The Phase 3 study (NCT06208150), titled "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide," is designed to evaluate talquetamab in combination therapies. The trial has an estimated enrollment of 795 participants with relapsed or refractory multiple myeloma who have received an anti-CD38 antibody and lenalidomide. It compares talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) against control arms of elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).

What this means

The primary completion of this Phase 3 trial indicates a significant milestone in the development of talquetamab for relapsed or refractory multiple myeloma. While specific results are not yet available, the completion suggests that the study has progressed through its main data collection phase. The findings from this large-scale trial will be crucial for understanding the potential role of talquetamab combination regimens in patients with advanced multiple myeloma who have limited treatment options after prior therapies.

Source

The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The study record for NCT06208150, titled "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide," was updated on April 23, 2026, on clinicaltrials.gov.